tradingkey.logo
tradingkey.logo
Search

Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026

ReutersSep 29, 2025 10:22 PM
facebooktwitterlinkedin
View all comments0

- AnaptysBio Inc ANAB.O:

  • ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026

  • ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026

  • ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICS

  • ANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA CO

  • ANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI & IMSIDOLIMAB

  • ANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI